Loading…
← CockpitCompetitor Analysis › 000999.SZ China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A000999.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chinese OTC and traditional-Chinese-medicine drugmaker owned by state conglomerate China Resources.

≈ A Chinese Bayer Consumer Health for OTC/TCM brandsMomentum leader 93
Mkt cap
$6.59B
US dollars, full cap
Free float
37%
of shares outstanding
$/day
$41.8M
20-day average traded
Fwd P/E
13.2×
forward earnings
ROIC−WACC
+4.4 pp
WACC 5.0%
Hurdle
-25 pp
Req g minus delivered
Next earnings
124 days
22 Mar 2027
Close · CNYCN¥26.40
1D0.0%
1W+5.4%
1M+2.3%
3M+5.6%
6M+5.9%
YTD-7.2%
1Y-9.0%
ATR %2.2%
52w lowhigh13.9% off high

What China Resources Sanjiu Medical & Pharmaceutical does

Chinese OTC and traditional-Chinese-medicine drugmaker owned by state conglomerate China Resources.

Sells over-the-counter remedies, mainly cold, stomach and skin products under its 999 brand, through pharmacy chains and wholesalers, so branding and pharmacy shelf presence matter more than doctor prescriptions. China Resources Group's drug-distribution network gives it reach across China. Traditional Chinese medicine granules and prescription drugs are smaller lines.

In one line: A Chinese Bayer Consumer Health for OTC/TCM brands.

Products and services

  • OTC branded medicines
  • Traditional Chinese medicine (TCM)
  • Prescription drugs

Customers

  • Pharmacies
  • Consumers
  • Hospitals

Where it sits in the supply chain

  • Health care
  • Branded OTC & TCM drugs
  • Consumer health & prescription TCM

What could go right

  • Consumer health brand extension
  • OTC channel expansion

What could go wrong

  • TCM regulatory/efficacy scrutiny
  • OTC price competition

Moat: narrow (brand, distribution, scale). Well-known consumer OTC brands and a nationwide pharmacy distribution network under China Resources.

Headquarters: Shenzhen, China · Founded: 1985 · Employees: 30,304

Named competitors

China Resources Sanjiu Medical & Pharmaceutical at a glance

Size China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $6.59B, the 354th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.40 on 18 Nov 2026.

Performance Over six months the shares gained 5.9%, against -4.5% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 4.2% over the last twelve months (peer median +16.4%); the operating margin is 13.7% (peer median 14.1%).

Valuation It trades at 13.2× forward earnings against a peer median of 21.6× (5th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -25 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.4 points above its cost of capital (5.0% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026000999.SZ 107Peer median 96
Six months, rebased to 100: China Resources Sanjiu Medical & Pharmaceutical against the median of its 20 peers (local-currency closes).

China Resources Sanjiu Medical & Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥31.0BCN¥31.4BCN¥27.4BCN¥24.5BCN¥17.9B
Revenue growth—+14%+12%+37%—
Gross profitCN¥18.0BCN¥16.1BCN¥13.8BCN¥12.7BCN¥9.45B
EBITDAn/aCN¥5.82BCN¥5.11BCN¥4.38BCN¥3.35B
Net incomeCN¥3.23BCN¥3.42BCN¥3.37BCN¥2.85BCN¥2.45B
Free cash flowCN¥3.69BCN¥4.34BCN¥3.69BCN¥3.36BCN¥2.12B
Capital expenditureCN¥1.40BCN¥1.27BCN¥790MCN¥857MCN¥952M
Total debtCN¥4.94BCN¥7.31BCN¥2.26BCN¥3.94BCN¥909M

Quarterly statements and history in the cockpit →

China Resources Sanjiu Medical & Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%ALKEM000963ORKA0126Z0BLTEBIOCON6883319926BANB6821IBRXCYTKMIRMSUPNLGND4528CORTKNSAGRF000999.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. China Resources Sanjiu Medical & Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%20×40×60×APTXALKEM000963BIOCON688331BANB6821SUPN4528CORTKNSA000999.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. China Resources Sanjiu Medical & Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%100%200%300%APTXALKEM000963688331SUPNLGNDKNSA000999.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. China Resources Sanjiu Medical & Pharmaceutical is the large dot.

China Resources Sanjiu Medical & Pharmaceutical competitors and peer comparison

Head to head with its named competitors (000999.SZ vs 000538.SZ vs 600085.SS vs 600750.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%
Beijing TongRenTang 600085.SS$4.91B-12%-17%8%28.7×1.7%
China Resources Jiangzhong Pharmaceutical 600750.SS$2.27B+4%-10%24%16.5×-1.9%
Bayer BAYN.DE$60.3B+48%0%13%12.3×n/a

How China Resources Sanjiu Medical & Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

China Resources Sanjiu Medical & Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure000999.SZPeer medianRank in peer set
1-month return+2.3%-0.7%9th highest of 21
6-month return+5.9%-4.5%8th highest of 20
Distance from 52-week high-13.9%-25.4%8th highest of 21
Revenue growth (TTM)+4.2%+16.4%5th lowest of 18
Operating margin13.7%14.1%9th lowest of 19
Forward P/E13.2×21.6×5th cheapest of 15
Growth the price implies (Req g, 7 yrs)-6.2%6.6%3rd least demanding of 11
Growth delivered (Del g)+18.4%+10.7%3rd highest of 11
Hurdle (Req g minus delivered)-24.5 pp-8.4 pp3rd least demanding of 11
ROIC minus cost of capital+4.4 pp-0.8 pp6th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
Biocon BIOCON.NSIndia$6.31B-15%+6%8%61.3×n/an/a
RemeGen 688331.SSChina$6.28B-24%+272%61%10.8×1.1%+303.3%
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%24.4×n/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%

Questions

Who are China Resources Sanjiu Medical & Pharmaceutical's main competitors?
Named competitors: Yunnan Baiyao (000538.SZ), Tong Ren Tang (600085.SS), Jiangzhong Pharmaceutical (600750.SS), Bayer (BAYN.DE). The cockpit's measured peer set (industry) also includes Apotex Health (APTX.TO), Alkem Laboratories (ALKEM.NS), Huadong Medicine (000963.SZ), Oruka Therapeutics (ORKA), Samsung Epis (0126Z0.KS), Belite Bio, Inc. ADR (BLTE).
Is China Resources Sanjiu Medical & Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 13.2× against a peer median of 21.6×, 5th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -25 pp: the price already allows for a slowdown.
How has China Resources Sanjiu Medical & Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +5.9% against -4.5% for the median peer; over one year -9.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.